Instrument Inactif

Autres langues Biocorrx Inc Other OTC

Actions

US09073C1062

Installations et services en soins de santé

Autres langues

15/05	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
31/03	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt
06/01	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026
10/12	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
14/11	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/08/25	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
29/07/25	BioCorRx Inc. announced that it has received $0.35 million in funding
15/05/25	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
31/03/25	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
31/03/25	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt
14/11/24	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024
13/08/24	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024
15/05/24	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
03/04/24	BioCorRx Inc. Announces Board Resignations
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
02/04/24	BioCorRx Reports Business Update for 2023
01/04/24	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
01/04/24	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt
28/02/24	BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
08/02/24	BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
08/02/24	BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors
09/01/24	BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President